A look at the upper heart chamber: the left atrium in chronic kidney disease

Area of Science:

• Cardiology
• Nephrology
• Clinical Trials

Background:

• Altered left ventricular (LV) mass and function characterize cardiomyopathy in chronic kidney disease (CKD).
• The left atrium (LA), sensitive to volume overload and diastolic dysfunction, predicts adverse outcomes in high-risk patients.
• LA size is an independent predictor of mortality and cardiovascular events in patients with hypertension and/or heart failure.

Purpose of the Study:

• To review the relationship between left atrial size and LV diastolic function.
• To examine the association between left atrial enlargement and cardiovascular and renal outcomes in CKD patients.
• To explore the potential of LA size as a surrogate endpoint in CKD.

Main Methods:

• Literature review focusing on LA size, LV diastolic function, and outcomes in CKD.
• Analysis of existing clinical trial data.
• Synthesis of evidence linking LA enlargement to cardiovascular and renal endpoints.

Main Results:

• Increased LA size is a strong predictor of mortality and major adverse cardiovascular events in both early and end-stage CKD.
• Some studies indicate a correlation between LA enlargement and CKD progression.
• Secondary analyses suggest LA size could serve as a surrogate endpoint in CKD.

Conclusions:

• Left atrial enlargement is a significant predictor of adverse outcomes in CKD patients.
• LA size may be a valuable surrogate endpoint for clinical trials in CKD, warranting further investigation.
• Understanding the role of the LA is crucial for managing cardiovascular risk in CKD.